Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF SEPTEMBER 03, 2009 FBO #2840
SOLICITATION NOTICE

A -- Highly Potent Cancer Therapeutics using Nanotechnology - S10-028 Highly Potent Cancer Therapeutics using Nanotechnology

Notice Date
9/1/2009
 
Notice Type
Combined Synopsis/Solicitation
 
NAICS
541711 — Research and Development in Biotechnology
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, Maryland, 21702
 
ZIP Code
21702
 
Solicitation Number
S10-028
 
Archive Date
10/14/2009
 
Point of Contact
Lynne Darby, Phone: 301 228 4021
 
E-Mail Address
darbyl@mail.nih.gov
(darbyl@mail.nih.gov)
 
Small Business Set-Aside
N/A
 
Description
Highly Potent Cancer Therapeutics using Nanotechnology RFP RFP S10-028. PROPOSALS MUST BE RECEIVED BY 3:00 P.M., Eastern Daylight Time, September 29, 2009. It is the Offerors responsibility to ensure that proposals are delivered by the due date and time required. Late proposals will not be accepted. All questions or requests for clarifications must be e-mailed (No telephone calls accepted) to Lynne Darby at darbyl@mail.nih.gov, or by facsimile at 301-228-4037 by 3:00 P.M., Eastern Daylight Time, September 15, 2009. Questions or requests directed to any other individual or outside the directives of this Solicitation will not be considered valid, nor will there be a response provided. SAIC-Frederick, Inc., on behalf of the The National Cancer Institute, NCI, is seeking offerors to submit proposals for nanotherapeutics that are in the post-optimization phase of the development cycle, and require evaluation in appropriate preclinical animal models of the disease for determination of both efficacy and safety profiles of the nanodevice and the targeted chemotherapeutic payload. The purpose of this Request for Proposals (RFP) is to identify and evaluate the potential of candidate nanotechnologies to improve the bioavailability, solubility, pharmacokinetics, or therapeutic index of a range of drugs that would otherwise fail as anti-cancer agents. The NCI Alliance for Nanotechnology is interested in identifying these technologies at academic institutions, nanotechnology-focused pharmaceutical companies, and biotechnology companies.This acquisition shall be conducted in a two-Phase approach. Once received, all proposals will be evaluated on the basis of technical merit, and a decision will be made to select a minimum of one, and possibly multiple awards.Specifics are outlined in detail in the attached Request for Proposals, S10-028.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF/S10-028/listing.html)
 
Place of Performance
Address: Contractor's site., United States
 
Record
SN01935913-W 20090903/090902004654-f89c3c3c3c6e81585c9a748ba156f33c (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.